Avalon GloboCare formed Avactis Biosciences to develop CAR-T therapies


Avalon GloboCare, a leading global developer of cell-based technologies and therapeutics, formed a new wholly owned subsidiary, Avactis Biosciences, which will be focused on accelerating commercial activities related to its proprietary Chimeric Antigen Receptor (CAR)-T technologies. 

The new subsidiary is designed to integrate and optimize the Company’s global scientific and clinical resources. CAR-T is a novel and revolutionary cancer immunotherapy that involves genetically modifying T cells to activate the immune system to recognize and destroy cancer cells.

Avalon GloboCare’s main affiliated clinical facility, the Hebei Yanda LuDaopei Hospital in Beijing (China) has completed over 300 cases of CAR-T therapy targeting CD19, CD22 and CD123, making it the single largest medical institution in CAR-T therapy in the world. Avactis Biosciences will take on specific roles in CAR-T bio-manufacturing, standardization, and bio-banking for the LuDaopei Hospital network and other affiliated hospitals, as well as provision of collaborative research and training programs for clinicians and scientists who are involved in CAR-T therapy and technology development.

Headquartered in New Jersey (USA), Avalon GloboCare is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management. Through its subsidiary, GenExosome Technologies Inc., Avalon further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine.